Vertex Pharmaceuticals (VRTX) Net Income - Minority (2011 - 2018)

Vertex Pharmaceuticals has reported Net Income - Minority for 8 years, with the latest figure at -$28.4 million in Q3 2018.

• For the quarter ending Q3 2018, Net Income - Minority fell 133.13% year-over-year to -$28.4 million; the trailing twelve-month figure through Sep 2018 stood at -$28.4 million (down 133.13% YoY), and the FY2017 full-year result was -$13.7 million, up 92.44% from the prior year.
• Net Income - Minority for Q3 2018 stood at -$28.4 million, up from -$28.7 million in the prior quarter.
• The five-year high for Net Income - Minority was -$12.2 million in Q3 2017, with the low at -$196.0 million in Q2 2017.
• Average Net Income - Minority over 5 years is -$106.9 million, with a median of -$153.5 million recorded in 2015.
• Year-over-year, Net Income - Minority tumbled 654.87% in 2016 and soared 93.49% in 2017.
• Tracing VRTX's Net Income - Minority over 5 years: stood at -$21.2 million in 2014, then slumped by 625.6% to -$153.7 million in 2015, then retreated by 18.19% to -$181.6 million in 2016, then jumped by 92.44% to -$13.7 million in 2017, then tumbled by 106.64% to -$28.4 million in 2018.
• The last three Net Income - Minority figures came in at -$28.4 million (Q3 2018), -$28.7 million (Q2 2018), and -$29.8 million (Q1 2018), per Business Quant data.

Peer Comparison